Sana Biotechnology (NASDAQ:SANA) Issues Earnings Results, Beats Expectations By $0.02 EPS

Sana Biotechnology (NASDAQ:SANA - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.23) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.02, Zacks reports.

Sana Biotechnology Trading Up 2.0 %

Shares of SANA traded up $0.05 during trading hours on Friday, reaching $2.31. The company had a trading volume of 1,007,484 shares, compared to its average volume of 3,028,740. The firm has a 50 day simple moving average of $2.98 and a 200-day simple moving average of $3.19. The company has a market capitalization of $518.68 million, a price-to-earnings ratio of -1.67 and a beta of 1.63. Sana Biotechnology has a 12-month low of $1.52 and a 12-month high of $10.50.

Analysts Set New Price Targets

SANA has been the subject of a number of analyst reports. HC Wainwright restated a "buy" rating and set a $11.00 price objective on shares of Sana Biotechnology in a research report on Tuesday. Jefferies Financial Group initiated coverage on shares of Sana Biotechnology in a research report on Friday, March 14th. They set a "buy" rating and a $7.00 price objective for the company. TD Cowen upgraded shares of Sana Biotechnology from a "hold" rating to a "buy" rating in a research report on Wednesday, January 8th. Finally, Citizens Jmp upgraded shares of Sana Biotechnology from a "market perform" rating to an "outperform" rating and set a $5.00 price target for the company in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $10.80.

Remove Ads

Insider Activity

In related news, insider Fmr Llc sold 290,912 shares of the stock in a transaction dated Wednesday, January 8th. The shares were sold at an average price of $6.49, for a total value of $1,888,018.88. Following the sale, the insider now directly owns 4,541,511 shares of the company's stock, valued at approximately $29,474,406.39. This represents a 6.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 31.10% of the company's stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.